NFE2L2 and cardiovascular disorder: Our study provides novel evidence that both oral delivery of Cu(II)ATSM in mice, and in vitro Cu(II)ATSM treatment of HCASMC and HCM, significantly upregulates Nrf2 dependent antioxidant defenses which is likely to confer protection against cardiovascular diseases associated oxidative stress7.